Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ)
CNY 4.19
(-0.48%)
CNY 4.19
(-0.48%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.08 Billion CNY | -20.75% |
| 2022 | 1.36 Billion CNY | -1.39% |
| 2021 | 1.38 Billion CNY | -58.99% |
| 2020 | 3.38 Billion CNY | -10.02% |
| 2019 | 3.75 Billion CNY | -10.49% |
| 2018 | 4.19 Billion CNY | 13.8% |
| 2017 | 3.69 Billion CNY | 32.19% |
| 2016 | 2.79 Billion CNY | 18.42% |
| 2015 | 2.35 Billion CNY | 30.42% |
| 2014 | 1.8 Billion CNY | 461.57% |
| 2013 | 321.86 Million CNY | 36.9% |
| 2012 | 235.11 Million CNY | 20.66% |
| 2011 | 194.86 Million CNY | 44.49% |
| 2010 | 134.86 Million CNY | -22.47% |
| 2009 | 173.95 Million CNY | -11.23% |
| 2008 | 195.95 Million CNY | 10.12% |
| 2007 | 177.95 Million CNY | -11.88% |
| 2006 | 201.95 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 759.64 Million CNY | -24.43% |
| 2024 Q2 | 831.48 Million CNY | -13.89% |
| 2024 Q1 | 965.63 Million CNY | -10.91% |
| 2023 Q1 | 1.45 Billion CNY | 6.42% |
| 2023 Q3 | 1.15 Billion CNY | -10.73% |
| 2023 Q4 | 1.08 Billion CNY | -5.75% |
| 2023 FY | 1.08 Billion CNY | -20.75% |
| 2023 Q2 | 1.28 Billion CNY | -11.5% |
| 2022 Q2 | 1.64 Billion CNY | 22.29% |
| 2022 Q3 | 1.66 Billion CNY | 0.81% |
| 2022 Q4 | 1.36 Billion CNY | -17.62% |
| 2022 Q1 | 1.34 Billion CNY | -2.9% |
| 2022 FY | 1.36 Billion CNY | -1.39% |
| 2021 FY | 1.38 Billion CNY | -58.99% |
| 2021 Q3 | 1.64 Billion CNY | -29.29% |
| 2021 Q1 | 3.47 Billion CNY | 2.79% |
| 2021 Q2 | 2.32 Billion CNY | -33.19% |
| 2021 Q4 | 1.38 Billion CNY | -15.56% |
| 2020 Q1 | 4.07 Billion CNY | 8.41% |
| 2020 FY | 3.38 Billion CNY | -10.02% |
| 2020 Q2 | 3.74 Billion CNY | -8.22% |
| 2020 Q3 | 3.7 Billion CNY | -1.01% |
| 2020 Q4 | 3.38 Billion CNY | -8.64% |
| 2019 FY | 3.75 Billion CNY | -10.49% |
| 2019 Q3 | 3.69 Billion CNY | -1.96% |
| 2019 Q2 | 3.77 Billion CNY | -10.88% |
| 2019 Q1 | 4.23 Billion CNY | 0.84% |
| 2019 Q4 | 3.75 Billion CNY | 1.6% |
| 2018 Q4 | 4.19 Billion CNY | 3.03% |
| 2018 FY | 4.19 Billion CNY | 13.8% |
| 2018 Q1 | 3.63 Billion CNY | -1.49% |
| 2018 Q2 | 4.13 Billion CNY | 13.85% |
| 2018 Q3 | 4.07 Billion CNY | -1.52% |
| 2017 Q4 | 3.69 Billion CNY | 10.08% |
| 2017 FY | 3.69 Billion CNY | 32.19% |
| 2017 Q1 | 2.73 Billion CNY | -2.09% |
| 2017 Q2 | 3.35 Billion CNY | 22.62% |
| 2017 Q3 | 3.35 Billion CNY | 0.03% |
| 2016 FY | 2.79 Billion CNY | 18.42% |
| 2016 Q4 | 2.79 Billion CNY | 3.76% |
| 2016 Q3 | 2.69 Billion CNY | 4.71% |
| 2016 Q2 | 2.56 Billion CNY | 0.93% |
| 2016 Q1 | 2.54 Billion CNY | 7.99% |
| 2015 Q3 | 2.12 Billion CNY | 0.78% |
| 2015 Q1 | 2.05 Billion CNY | 13.47% |
| 2015 FY | 2.35 Billion CNY | 30.42% |
| 2015 Q2 | 2.1 Billion CNY | 2.73% |
| 2015 Q4 | 2.35 Billion CNY | 11.02% |
| 2014 Q4 | 1.8 Billion CNY | 18.07% |
| 2014 Q1 | 968.36 Million CNY | 200.86% |
| 2014 Q2 | 1.35 Billion CNY | 39.45% |
| 2014 FY | 1.8 Billion CNY | 461.57% |
| 2014 Q3 | 1.53 Billion CNY | 13.37% |
| 2013 Q4 | 321.86 Million CNY | -8.21% |
| 2013 FY | 321.86 Million CNY | 36.9% |
| 2013 Q1 | 227.36 Million CNY | -3.3% |
| 2013 Q2 | 227.86 Million CNY | 0.22% |
| 2013 Q3 | 350.66 Million CNY | 53.89% |
| 2012 FY | 235.11 Million CNY | 20.66% |
| 2012 Q3 | 229.86 Million CNY | 0.0% |
| 2012 Q2 | 229.86 Million CNY | 12.2% |
| 2012 Q4 | 235.11 Million CNY | 2.28% |
| 2012 Q1 | 204.86 Million CNY | 5.13% |
| 2011 Q1 | 144.86 Million CNY | 7.42% |
| 2011 Q3 | 151 Million CNY | -7.28% |
| 2011 Q4 | 194.86 Million CNY | 29.05% |
| 2011 FY | 194.86 Million CNY | 44.49% |
| 2011 Q2 | 162.86 Million CNY | 12.43% |
| 2010 Q2 | 167.86 Million CNY | -7.7% |
| 2010 Q3 | 137.86 Million CNY | -17.87% |
| 2010 Q1 | 181.86 Million CNY | 4.55% |
| 2010 Q4 | 134.86 Million CNY | -2.18% |
| 2010 FY | 134.86 Million CNY | -22.47% |
| 2009 FY | 173.95 Million CNY | -11.23% |
| 2009 Q2 | 169.09 Million CNY | 0.0% |
| 2009 Q4 | 173.95 Million CNY | 0.0% |
| 2008 FY | 195.95 Million CNY | 10.12% |
| 2007 FY | 177.95 Million CNY | -11.88% |
| 2006 FY | 201.95 Million CNY | 0.0% |